1. Home
  2. PRVA vs TWST Comparison

PRVA vs TWST Comparison

Compare PRVA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Privia Health Group Inc.

PRVA

Privia Health Group Inc.

N/A

Current Price

$21.50

Market Cap

2.8B

Sector

Technology

ML Signal

N/A

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

N/A

Current Price

$47.08

Market Cap

3.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRVA
TWST
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.0B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
PRVA
TWST
Price
$21.50
$47.08
Analyst Decision
Strong Buy
Buy
Analyst Count
14
8
Target Price
$30.50
$48.75
AVG Volume (30 Days)
653.1K
1.5M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
0.11
N/A
Revenue
$1,736,390,000.00
$376,572,000.00
Revenue This Year
$23.19
$18.89
Revenue Next Year
$13.51
$15.28
P/E Ratio
$197.27
N/A
Revenue Growth
4.74
20.32
52 Week Low
$18.78
$23.30
52 Week High
$26.51
$57.88

Technical Indicators

Market Signals
Indicator
PRVA
TWST
Relative Strength Index (RSI) 39.93 56.28
Support Level $19.54 $25.67
Resistance Level $24.04 N/A
Average True Range (ATR) 0.73 3.06
MACD 0.01 -0.43
Stochastic Oscillator 27.50 30.76

Price Performance

Historical Comparison
PRVA
TWST

About PRVA Privia Health Group Inc.

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Share on Social Networks: